Efficient [(18)F]AlF Radiolabeling of ZHER3:8698 Affibody Molecule for Imaging of HER3 Positive Tumors.
Loading...
Files
Embargo End Date
ICR Authors
Authors
Da Pieve, C
Allott, L
Martins, CD
Vardon, A
Ciobota, DM
Kramer-Marek, G
Smith, G
Allott, L
Martins, CD
Vardon, A
Ciobota, DM
Kramer-Marek, G
Smith, G
Document Type
Journal Article
Date
2016-08-17
Date Accepted
2016-06-29
Abstract
The human epidermal growth factor receptor 3 (HER3) is overexpressed in several cancers, being linked to a more resistant phenotype and hence leading to poor patient prognosis. Imaging HER3 is challenging owing to the modest receptor number (<50000 receptors/cell) in overexpressing cancer cells. Therefore, to image HER3 in vivo, high target affinity PET probes need to be developed. This work describes two different [(18)F]AlF radiolabeling strategies of the ZHER3:8698 affibody molecule specifically targeting HER3. The one-pot radiolabeling of ZHER3:8698 performed at 100 °C and using 1,4,7-triazanonane-1,4,7-triacetate (NOTA) as chelator resulted in radiolabeled products with variable purity attributed to radioconjugate thermolysis. An alternative approach based on the inverse electron demand Diels-Alder (IEDDA) reaction between a novel tetrazine functionalized 1,4,7-triazacyclononane-1,4-diacetate (NODA) chelator and the trans-cyclooctene (TCO) functionalized affibody molecule was also investigated. This method enabled the radiolabeling of the protein at room temperature. The [(18)F]AlF-NOTA-ZHER3:8698 and [(18)F]AlF-NODA-ZHER3:8698 conjugates showed a specific uptake at 1 h after injection in high HER3-expressing MCF-7 tumors of 4.36 ± 0.92% ID/g and 4.96 ± 0.65% ID/g, respectively. The current results are encouraging for further investigation of [(18)F]AlF-NOTA-ZHER3:8698 as a HER3 imaging agent.
Citation
Bioconjugate chemistry, 2016, 27 (8), pp. 1839 - 1849
Source Title
Publisher
AMER CHEMICAL SOC
ISSN
1043-1802
eISSN
1520-4812
Research Team
PET Radiochemistry
Preclinical Molecular Imaging
Preclinical Molecular Imaging